Veterinary pain management market to hit $2.5B

The market for pain management in veterinary care is expected to reach a value of $2.5 billion by the year 2027, according to a report by MarketsandMarkets, which provides B2B research on high growth niche opportunities and threats. The market was valued at $1.8 billion in 2022, according to a news release. The increase across the market is projected at a Compound Annual Growth Rate (CAGR) of 6.7% between 2022 and 2027.  

In veterinary practices, pain management is typically achieved with medications and devices. Medications for pets include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), local anesthetic, disease-modifying osteoarthritic drugs and alpha-2 agonists.  

In 2021, NSAIDs accounted for the largest share of the veterinary pain management drugs market. The large share of this segment can be attributed to the widespread adoption of NSAIDs for a range of applications due to the low cost of these drugs. 

Based on animal type, the market is segmented into companion animals and livestock animals. The cat segment of companion animals accounted for the largest share of the veterinary pain management market in 2021, according to the report. The large share of this segment can be attributed to the increasing cat ownership, and rising pet healthcare expenditure. 

By route of administration, oral use is forecasted to grow at the fastest rate by 2027, compared to parenteral and topical administration. The oral segment also led in 2021, as the medication is easy to dispense, store and administer. 

The veterinary pain management market is segmented into joint pain, post-operative pain, cancer and other applications. The joint pain segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the growing geriatric pet population, the growing prevalence of osteoarthritis and musculoskeletal disorders, and the increasing population of obese and overweight pets. 

Learn more about this report on the MarketsandMarkets website.  

  • Please enter a comment

Name *
Email address *
Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

More news

World Veterinary Dermatology Day


Artificial insemination market to grow to $3B by 2028


February is National Pet Dental Health Month


Falling markets? Don't panic, it's not the first time


Treatment of canine chronic cutaneous lupus erythematosus with oclacitinib




News of interest


Copyright © 2023 - All Rights Reserved
ISSN 2768-198X